Houssiau Hélène, Seront Emmanuel
Department of Medical Oncology, Centre Hospitalier de Jolimont, Rue Ferrer 159, 7100 Haine Saint Paul, Belgium.
Cancers (Basel). 2022 Mar 24;14(7):1640. doi: 10.3390/cancers14071640.
Urothelial carcinoma is an aggressive cancer and development of metastases remains a challenge for clinicians. Immune checkpoint inhibitors (ICIs) are significantly improving the outcomes of patients with metastatic urothelial cancer (mUC). These agents were first used in monotherapy after failure of platinum-based chemotherapy, but different strategies explored the optimal use of ICIs in a first-line metastatic setting. The "maintenance" strategy consists of the introduction of ICIs in patients who experienced benefit from first-line chemotherapy in a metastatic setting. This allows an earlier use of ICIs, without waiting for disease progression. We review the optimal management of mUC in the era of ICIs, based on the key clinical messages arising from the pivotal trials.
尿路上皮癌是一种侵袭性癌症，转移的发生对临床医生来说仍然是一项挑战。免疫检查点抑制剂（ICI）正在显著改善转移性尿路上皮癌（mUC）患者的治疗效果。这些药物最初是在铂类化疗失败后用于单药治疗，但不同的策略探索了ICI在一线转移性治疗中的最佳使用方法。“维持”策略是指在转移性环境中从一线化疗中获益的患者中引入ICI。这使得ICI能够更早使用，而无需等待疾病进展。我们根据关键试验得出的关键临床信息，综述了ICI时代mUC的最佳管理方法。
